BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Roche readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Roche's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04895436-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04895436)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy to Assess Change in Disease Activity and Adverse Events of Oral Veneto
 clax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurri
 ng Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0489
 5436
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Multiple Therapies in Biomarker-selected Participants With Resect
 able Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03148418-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03148418)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Participants Previou
 sly Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Ate
 zolizumab Study (IMbrella A)\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03148418
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03758989-4915@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03758989)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of PET Adapted Therapy and Non-invasive Monitoring for Pre
 viously Untreated Limited Stage Diffuse Large B Cell Lymphoma\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03758989
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-525@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Baxfendy (Baxdrostat): Phase 2 readout est. (NCT07222917)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 2\, Hypertension.\nStudy: A Phase
  IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Bax
 drostat Compared With Baxdrostat on Albuminuria in Participants With Chron
 ic Kidney Disease and High Blood Pressure.\nEstimated primary completion: 
 10 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bax
 drostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07222917
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077723-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT04077723)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Evaluate the Safety\, Pharmacokinetics and Preliminary Anti-Tumor Act
 ivity of Englumafusp Alfa in Combination With Obinutuzumab and in Combinat
 ion With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Part
 icipants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma\nEstimated
  primary completion: 28 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04077723
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910528-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:afimkibart: Phase 2 readout est. (NCT05910528)
DESCRIPTION:afimkibart\, phase 2\, Crohn's Disease.\nStudy: Afimkibart (RO7
 790121) for the Treatment of Moderate to Severe Active Crohn's Disease\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05910528
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208773-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07208773)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07208773
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2016@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Alecensa (Alectinib): Phase 3 readout est. (NCT05170204)
DESCRIPTION:Alecensa (Alectinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Therapies in 
 Cohorts of Participants With Locally Advanced\, Unresectable\, Stage III N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517020
 4
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589986-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:afimkibart: Phase 3 readout est. (NCT06589986)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for 
 Induction and Maintenance Therapy in Participants With Moderately to Sever
 ely Active Ulcerative Colitis\nEstimated primary completion: 30 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589986
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: IMGN63
 2 as Monotherapy or With Venetoclax and/or Azacitidine for Participants Wi
 th CD123-Positive Acute Myeloid Leukemia\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4086264
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06241846-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tambotatug pelitecan: Phase 2 readout est. (NCT06241846)
DESCRIPTION:Tambotatug pelitecan\, phase 2.\nStudy: A Phase II Study to Eva
 luate the Safety\, Efficacy\, and Pharmacokinetics of YL201 in Patients Wi
 th mCRPC\nEstimated primary completion: February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06241846
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535244-3151@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Cevostamab: Phase 1/2 readout est. (NCT05535244)
DESCRIPTION:Cevostamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation An
 tigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myelom
 a\nEstimated primary completion: 26 February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05535244
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02320435-2241@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT02320435)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: A Safety and Efficacy Extension S
 tudy of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a 
 Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial\nEstimated primary c
 ompletion: 28 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02320435
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04873362-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04873362)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study Evaluating the Efficacy
  and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine 
 for Participants With HER2-Positive Breast Cancer at High Risk of Recurren
 ce Following Preoperative Therapy\nEstimated primary completion: 31 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048733
 62
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434234-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT05434234)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2.\nStudy: A Study of YL201 in P
 atients With Advanced Solid Tumors\nEstimated primary completion: 6 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-peli
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05434234
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137598-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:afimkibart: Phase 2 readout est. (NCT07137598)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study to
  Assess the Efficacy and Safety of RO7790121 in Participants With Moderate
  to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot To
 lerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)\nE
 stimated primary completion: 17 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07137598
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894239-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT05894239)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, Breast Cancer.\nStudy: A Study
  to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phe
 sgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-
 Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer\nEstima
 ted primary completion: 3 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05894239
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: Study of Venet
 oclax in Combination With Carfilzomib and Dexamethasone in Participants Wi
 th Relapsed or Refractory Multiple Myeloma (MM)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02899052
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161258-11333@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Fenebrutinib: Phase 2 readout est. (NCT07161258)
DESCRIPTION:Fenebrutinib\, phase 2\, Multiple Sclerosis.\nStudy: A Pharmaco
 kinetics (PK)\, Pharmacodynamics (PD)\, Safety and Tolerability Study of F
 enebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis 
 (RMS)\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fenebrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07161258
URL:https://assetmemo.bio/drug/fenebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02650401-2220@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Entrectinib: Phase 1/2 readout est. (NCT02650401)
DESCRIPTION:Entrectinib\, phase 1/2.\nStudy: Study Of Entrectinib (Rxdx-101
 ) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or
  Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02650401
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT00781612)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Safety Extension Study of Tra
 stuzumab Emtansine in Participants Previously Treated With Trastuzumab Emt
 ansine Alone or in Combination With Other Anti-Cancer Therapy in One of th
 e Parent Studies\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT00781612
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Atezolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies
  as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878769-1435@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:astegolimab: Phase 3 readout est. (NCT05878769)
DESCRIPTION:astegolimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: A Study to Evaluate the Long-Term Safety of Astegolimab in Partici
 pants With Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/astegolimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05878769
URL:https://assetmemo.bio/drug/astegolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05112965)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: An Extension Study in Participa
 nts Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Spo
 nsored Atezolizumab Study (IMbrella C)\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 112965
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04401748-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04401748)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Study Of Venetoclax Tablet With I
 ntravenous or Subcutaneous Azacitidine to Assess Change in Disease Activit
 y In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic S
 yndrome\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04401748
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007793-525@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07007793)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3.\nStudy: Parent Study: A Study 
 to Assess Efficacy and Safety of Baxdrostat in Participants With Primary A
 ldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA
  Main Study.\nEstimated primary completion: 27 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07007793
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524871-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04524871)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Pa
 tients With Advanced Liver Cancers (Morpheus-Liver)\nEstimated primary com
 pletion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04524871
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06096779)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A St
 udy Evaluating Atezolizumab\, With or Without Bevacizumab\, in Participant
 s With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
 hosis\nEstimated primary completion: 30 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06096779
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04639050-670@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Trontinemab: Phase 1/2 readout est. (NCT04639050)
DESCRIPTION:Trontinemab\, phase 1/2\, Alzheimer's Disease.\nStudy: Brainshu
 ttle AD: A Multiple Ascending Dose Study to Investigate the Safety\, Toler
 ability\, Pharmacokinetics\, and Pharmacodynamics of RO7126209 Following I
 ntravenous Infusion in Participants With Prodromal or Mild to Moderate Alz
 heimer's Disease\nEstimated primary completion: 31 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04639050
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04594798-4915@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04594798)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Polatuzumab V
 edotin\, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL\nE
 stimated primary completion: 31 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04594798
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07054190)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, Breast Cancer.\nStudy: A Study
  to Test Inavolisib Treatments in Participants With Early-Stage\, PIK3CA-M
 utated Breast Cancer\nEstimated primary completion: 31 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07054190
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979336-44@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:vixarelimab: Phase 2 readout est. (NCT06979336)
DESCRIPTION:vixarelimab\, phase 2\, Ulcerative Colitis.\nStudy: A Study to 
 Evaluate the Efficacy\, Safety\, and Pharmacokinetics (PK) of RO7837195 in
  Participants With Moderately to Severely Active Ulcerative Colitis (UC)\n
 Estimated primary completion: 25 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vixarelimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06979336
URL:https://assetmemo.bio/drug/vixarelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2241@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: A
  Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participant
 s With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced S
 olid Tumors\nEstimated primary completion: 31 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05593094
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06084936)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: A Study to Evaluate Glofitamab 
 as a Single Agent vs. Investigator's Choice in Participants With Relapsed/
 Refractory Mantle Cell Lymphoma\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0608493
 6
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416526-11331@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07416526)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: A Clinical Study to Evaluate the E
 ffects of NXT007 Compared to Factor VIII Prophylaxis in Participants With 
 Hemophilia A\nEstimated primary completion: 23 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zemocimig#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07416526
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05207670-6083@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0520767
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Study Ev
 aluating the Safety\, Efficacy\, and Pharmacokinetics of Mosunetuzumab Mon
 otherapy in Participants With Select B-Cell Malignancies\nEstimated primar
 y completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05207670
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-4915@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06047080)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: An Open-Label Study Comp
 aring Glofitamab and Polatuzumab Vedotin + Rituximab\, Cyclophosphamide\, 
 Doxorubicin\, and Prednisone Versus Pola-R-CHP in Previously Untreated Pat
 ients With Large B-Cell Lymphoma\nEstimated primary completion: 1 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047080
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06534983-11325@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Autogene cevumeran: Phase 2 readout est. (NCT06534983)
DESCRIPTION:Autogene cevumeran\, phase 2.\nStudy: A Study to Evaluate the E
 fficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab A
 lone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (
 MIUC)\nEstimated primary completion: 10 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/autogene-cevumeran#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06534983
URL:https://assetmemo.bio/drug/autogene-cevumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:enicepatide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:enicepatide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study o
 f Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Over
 weight\nEstimated primary completion: 12 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612151-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06612151)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-3
 02)\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06612151
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629597-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06629597)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Nasopharyngeal Carcinoma.\nStu
 dy: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal C
 arcinoma (TAISHAN-301)\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-pelitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0662959
 7
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269004-6975@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT05269004)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: A Rollover 
 Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Pati
 ents With Multiple Sclerosis\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ocrelizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05269004
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221500-10973@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:bexobrutideg: Phase 2 readout est. (NCT07221500)
DESCRIPTION:bexobrutideg\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton
 's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak C
 LL-201)\nEstimated primary completion: January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07221500
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448038-1127@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selnoflast: Phase 2 readout est. (NCT07448038)
DESCRIPTION:Selnoflast\, phase 2\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Study to Evaluate the Efficacy\, Safety\, Pharmacodynamics (PD)\
 , and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammatio
 n in Participants With Atherosclerosis at Risk for Major Adverse Cardiac E
 vents\nEstimated primary completion: 31 January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/selnoflast#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07448038
URL:https://assetmemo.bio/drug/selnoflast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258979-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07258979)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Nasopharyngeal Carcinoma.\nS
 tudy: A Study of YL201 in Combination With Toripalimab and With or Without
  Cisplatin in Nasopharyngeal Carcinoma.\nEstimated primary completion: Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatu
 g-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07258979
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112872-158@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280205
DTEND;VALUE=DATE:20280206
SUMMARY:Tifeglipron: Phase 2 readout est. (NCT07112872)
DESCRIPTION:Tifeglipron\, phase 2\, Type 2 Diabetes.\nStudy: A Study to Com
 pare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutid
 e in People With Type 2 Diabetes\nEstimated primary completion: 5 February
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tifeglipron#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071128
 72
URL:https://assetmemo.bio/drug/tifeglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686120-525@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07686120)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participant
 s With Uncontrolled Hypertension.\nEstimated primary completion: 9 Februar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076861
 20
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169578-670@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07169578)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Participants With Early Symptomatic Alzheimer's Disease\nE
 stimated primary completion: 16 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07169578
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170150-670@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07170150)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Clinical
  Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's D
 isease\nEstimated primary completion: 16 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07170150
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-525@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06268873)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Study to Investigate the Efficacy and Safety of Baxdrostat in Combina
 tion With Dapagliflozin on CKD Progression in Participants With CKD and Hi
 gh Blood Pressure.\nEstimated primary completion: 24 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06268873
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670416-159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:enicepatide: Phase 3 readout est. (NCT07670416)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Study to Evaluate th
 e Effects of Enicepatide in Participants With Obesity or Overweight\, With
  or Without Type 2 Diabetes\nEstimated primary completion: 24 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07670416
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Atezolizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study Evalua
 ting the Efficacy and Safety of Biomarker-Driven Therapies in Patients Wit
 h Persistent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primar
 y completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04931342
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416604-11331@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07416604)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: A Clinical Study to Evaluate the E
 ffects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophi
 lia A\nEstimated primary completion: 29 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zemocimig#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07416604
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Particip
 ants Receiving Oral Venetoclax in Combination With Intravenously Infused O
 binutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphoc
 ytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287150-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07287150)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2.\nStudy: A Study to Test Inavoli
 sib Treatment in Participants With Metastatic Castration-Resistant Prostat
 e Cancer\nEstimated primary completion: 31 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/inavolisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07287150
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408638-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04408638)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: A Phase III Study Evaluating Gl
 ofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Com
 bination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refr
 actory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044
 08638
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9126@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Giredestrant: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Giredestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared Wit
 h Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive
 \, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Th
 erapy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487896-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07487896)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of YL201 Versus Investigator's Choice of Chemotherap
 y in Participants With Locally Advanced or Metastatic Esophageal Squamous 
 Cell Carcinoma After Failure of First-Line Therapy\nEstimated primary comp
 letion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07487896
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816328-5789@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Xolair (Omalizumab): Phase 3 readout est. (NCT07816328)
DESCRIPTION:Xolair (Omalizumab)\, phase 3\, Chronic Spontaneous Urticaria.\
 nStudy: Investigation of a Remibrutinib- and Omalizumab-based Treatment Al
 gorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately 
 Controlled by H1-antihistamines Within 24 Weeks\nEstimated primary complet
 ion: 24 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/oma
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07816328
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797610-5037@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Sefaxersen: Phase 3 readout est. (NCT05797610)
DESCRIPTION:Sefaxersen\, phase 3\, IgA Nephropathy.\nStudy: A Study to Eval
 uate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants Wit
 h Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression\n
 Estimated primary completion: 25 May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sefaxersen#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05797610
URL:https://assetmemo.bio/drug/sefaxersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846683-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07846683)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimk
 ibart in Participants With Moderately to Severely Active Ulcerative Coliti
 s\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07846683
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05883748-9334@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bitopertin: Phase 2/3 readout est. (NCT05883748)
DESCRIPTION:Bitopertin\, phase 2/3\, Erythropoietic Protoporphyria.\nStudy:
  HELIOS: Open-Label\, Long-Term Extension Study to Investigate the Safety\
 , Tolerability\, and Efficacy of DISC-1459 (Bitopertin) in Participants Wi
 th EPP or XLP\nEstimated primary completion: June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bitopertin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05883748
URL:https://assetmemo.bio/drug/bitopertin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039619-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05039619)
DESCRIPTION:Obinutuzumab\, phase 2\, Lupus Nephritis.\nStudy: A Study to Ev
 aluate the Efficacy\, Safety\, and Pharmacokinetics of Obinutuzumab in Ado
 lescents With Active Class III or IV Lupus Nephritis and the Safety and PK
  of Obinutuzumab in Pediatric Participants\nEstimated primary completion: 
 15 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05039619
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296798-2241@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05296798)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: A Study to Evalua
 te the Efficacy and Safety of Giredestrant in Combination With Phesgo (Per
 tuzumab\, Trastuzumab\, and Hyaluronidase-zzxf) Versus Phesgo in Participa
 nts With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Can
 cer)\nEstimated primary completion: 15 June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05296798
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419374-1159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pegozafermin: Phase 3 readout est. (NCT06419374)
DESCRIPTION:Pegozafermin\, phase 3\, MASH / NASH.\nStudy: A Study to Evalua
 te the Efficacy and Safety of Pegozafermin in Participants With Compensate
 d Cirrhosis Due to MASH\nEstimated primary completion: 30 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06419374
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387471-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07387471)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Study to Assess Change in Disease
  Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed
  or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic
  Lymphoma (LPL)\nEstimated primary completion: July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07387471
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Patients Previously 
 Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezoliz
 umab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351045-159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351045)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight Without Type 2 Diabetes\nEstimated primary completion: 24 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 51045
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3151@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cevostamab: Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Cevostamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Safety and Efficacy of Multiple Treatments in Participants With
  Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351058-159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351058)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight and Type 2 Diabetes\nEstimated primary completion: 7 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073510
 58
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100106-9089@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Vustanaciclib: Phase 1/2 readout est. (NCT07100106)
DESCRIPTION:Vustanaciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: A Study to Evaluate the Effect of GDC-4198 Alone and in Combinati
 on With Giredestrant Versus Abemaciclib and Giredestrant in Participants W
 ith Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+)\, Huma
 n Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer\nEstimat
 ed primary completion: 31 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vustanaciclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07100106
URL:https://assetmemo.bio/drug/vustanaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838194-11331@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07838194)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: Clinical Trial of NXT007 for the P
 rophylactic Treatment of Hemophilia A in Infants and Children\nEstimated p
 rimary completion: 30 September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zemocimig#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07838194
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843485-162@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843485)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Type 2 Diabetes\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/petrelint
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07843485
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368998-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07368998)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: To Study the Effect of Inavolisib in Combination With Fulves
 trant in Participants With Breast Cancer\nEstimated primary completion: 31
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inavol
 isib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07368998
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407933-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07407933)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Small Cell Lung Cancer.\nStu
 dy: A Study of YL201 in Combination With Other Anti-Cancer Therapies in Pa
 tients With Advanced Solid Tumors\nEstimated primary completion: November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-peli
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07407933
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793215-2217@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Divarasib: Phase 3 readout est. (NCT06793215)
DESCRIPTION:Divarasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versu
 s Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participant
 s With Previously Untreated\, KRAS G12C-Mutated\, Advanced or Metastatic N
 on-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 30 N
 ovember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/divaras
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6793215
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555938-3151@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cevostamab: Phase 3 readout est. (NCT07555938)
DESCRIPTION:Cevostamab\, phase 3\, Multiple Myeloma.\nStudy: Cevostamab in 
 Combination With Pomalidomide and Dexamethasone Versus Standard of Care in
  Participants With Previously Treated Multiple Myeloma\nEstimated primary 
 completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cevostamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07555938
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827573-9126@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Giredestrant: Phase 3 readout est. (NCT07827573)
DESCRIPTION:Giredestrant\, phase 3.\nStudy: A Study to Learn How Well Parti
 cipants With a Specific Type of Early Breast Cancer (ER-Positive\, HER2-Ne
 gative) Tolerate and Stay on Treatment With Giredestrant and How They Feel
  During Treatment\nEstimated primary completion: 30 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07827573
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405801-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07405801)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Phase II Study Evaluating the Efficacy and Safety of Inavo
 lisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus
  Fulvestrant in Participants With Advanced Breast Cancer\nEstimated primar
 y completion: 19 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07405801
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843498-162@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843498)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity\nEstimated primary completion: 21 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/petrelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07843498
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819878-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819878)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction and Maintenance Therapy With Afimk
 ibart (RO7790121) in Participants With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06819878
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819891-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819891)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121
 ) in Participants With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06819891
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803783-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07803783)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Pancreatic Ductal Adenocarcino
 ma.\nStudy: A Study to Compare the Efficacy and Safety of YL201 With Stand
 ard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failu
 re of Gemcitabine-Based Systemic Chemotherapy\nEstimated primary completio
 n: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamb
 otatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07803783
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06318169-1159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pegozafermin: Phase 3 readout est. (NCT06318169)
DESCRIPTION:Pegozafermin\, phase 3\, MASH / NASH.\nStudy: A Study Evaluatin
 g the Efficacy and Safety of Pegozafermin in Participants With MASH and Fi
 brosis (ENLIGHTEN-Fibrosis)\nEstimated primary completion: February 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06318169
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423104-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07423104)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Cladribine\, Low Dose Cytarabine\, and Venetoclax in Treatment of Relap
 sed/Refractory or Secondary Acute Myeloid Leukemia\nEstimated primary comp
 letion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07423104
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712643-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04712643)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A St
 udy of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in P
 atients With Untreated Heaptocellular Carcionma\nEstimated primary complet
 ion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04712643
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03075696-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03075696)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Dose
  Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combi
 nation With Obinutuzumab\, Administered After a Fixed\, Single Pre-treatme
 nt Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell No
 n-hodgkin's Lymphoma\nEstimated primary completion: 30 March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03075696
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889648-159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:enicepatide: Phase 3 readout est. (NCT07889648)
DESCRIPTION:enicepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Clinical Stu
 dy to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participan
 ts With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose
 -Lowering Medications\nEstimated primary completion: 2 April 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07889648
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-3151@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Cevostamab: Phase 2 readout est. (NCT07825064)
DESCRIPTION:Cevostamab\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab in 
 Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR 
 T-Cell Therapy in Participants With Previously Treated Multiple Myeloma\nE
 stimated primary completion: 13 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413939-11326@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Bizrolertinib: Phase 2/3 readout est. (NCT07413939)
DESCRIPTION:Bizrolertinib\, phase 2/3\, HER2-Positive Breast Cancer.\nStudy
 : RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitab
 ine in People With Locally Advanced or Metastatic Breast Cancer That is Hu
 man Epidermal Growth Factor Receptor 2 (HER2)-Positive\nEstimated primary 
 completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bizrolertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07413939
URL:https://assetmemo.bio/drug/bizrolertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Atezolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Participants With Breast Cancer\nEstimated primary completi
 on: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atez
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04802759
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739758-2817@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07739758)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of YL201 in Combination With Serplulimab in Participants With Tr
 eatment-naïve Extensive-stage Small Cell Lung Cancer\nEstimated primary c
 ompletion: June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07739758
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Itovebi (Inavolisib): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Itovebi (Inavolisib)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestrant 
 With or Without Palbociclib in Participants With Advanced Breast Cancer (A
 BC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/inavolisib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174310-1655@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Prasinezumab: Phase 3 readout est. (NCT07174310)
DESCRIPTION:Prasinezumab\, phase 3\, Parkinson's Disease.\nStudy: A Study t
 o Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Par
 ticipants With Early-Stage Parkinson's Disease\nEstimated primary completi
 on: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pra
 sinezumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07174310
URL:https://assetmemo.bio/drug/prasinezumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806033-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06806033)
DESCRIPTION:Obinutuzumab\, phase 2.\nStudy: Evaluate Optimization of CRS Pr
 ofile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL\nEst
 imated primary completion: 31 July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06806033
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503340-6975@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ocrelizumab: Phase 2 readout est. (NCT07503340)
DESCRIPTION:Ocrelizumab\, phase 2\, Multiple Sclerosis.\nStudy: A Study to 
 Evaluate Pharmacokinetics\, Safety\, Tolerability\, Immunogenicity and Pha
 rmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Childre
 n and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07503340
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516093-10973@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:bexobrutideg: Phase 3 readout est. (NCT07516093)
DESCRIPTION:bexobrutideg\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL\nEstimated primary co
 mpletion: October 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bexobrutideg#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07516093
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-2649@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy i
 n Pediatric and Young Adult Participants With Relapsed/Refractory Mature B
 -Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937852-11333@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Fenebrutinib: Phase 3 readout est. (NCT07937852)
DESCRIPTION:Fenebrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participant
 s With Multiple Sclerosis (MS)\nEstimated primary completion: 30 November 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/fenebrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079378
 52
URL:https://assetmemo.bio/drug/fenebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-525@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06677060)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Heart Failure.\nStudy: Phase 
 III Study Investigating Heart Failure and Cardiovascular Death With Baxdro
 stat in Combination With Dapagliflozin\nEstimated primary completion: 17 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdros
 tat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06677060
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-525@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06742723)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Renal Outcomes and Cardiovascular Mortality Study to Investigate the 
 Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Par
 ticipants With Chronic Kidney Disease and High Blood Pressure\nEstimated p
 rimary completion: 18 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/baxdrostat#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675955-6975@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT06675955)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: An Extensio
 n Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function a
 nd Provide Continued Ocrelizumab Treatment\nEstimated primary completion: 
 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ocr
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06675955
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158242-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:afimkibart: Phase 3 readout est. (NCT07158242)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to E
 valuate the Pharmacokinetics\, Safety and Efficacy of Afimkibart (RO779012
 1) in Children With Moderately to Severely Active Ulcerative Colitis\nEsti
 mated primary completion: 31 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07158242
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298421-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07298421)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Pharmacokinetics\, Effectiveness and Safety of Afimkibart for Induc
 tion and Maintenance Therapy in Children With Moderately to Severely Activ
 e Crohn's Disease\nEstimated primary completion: 31 May 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07298421
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843472-162@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20300728
DTEND;VALUE=DATE:20300729
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843472)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Established Cardiovascular Disease\nEstimated primar
 y completion: 28 July 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/petrelintide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07843472
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04246086-6083@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20300906
DTEND;VALUE=DATE:20300907
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04246
 086)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab +
  Lenalidomide (+Len)\, and the Safety\, Tolerability\, and Pharmacokinetic
 s of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymp
 homa\nEstimated primary completion: 6 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04246086
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181109-532@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20300923
DTEND;VALUE=DATE:20300924
SUMMARY:Zilebesiran: Phase 3 readout est. (NCT07181109)
DESCRIPTION:Zilebesiran\, phase 3\, Hypertension.\nStudy: Zilebesiran in Pa
 tients With Hypertension Not Adequately Controlled and With Either Establi
 shed Cardiovascular Disease or High Risk for Cardiovascular Disease\nEstim
 ated primary completion: 23 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/zilebesiran#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07181109
URL:https://assetmemo.bio/drug/zilebesiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Atezolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Patients With Metastatic or Locally Advanced Breast Cancer\
 nEstimated primary completion: 30 September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02966756-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02966756)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Venetoclax in Participants With Relapsed or Refractory Chronic Ly
 mphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ven
 etoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02966756
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05968326-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05968326)
DESCRIPTION:Atezolizumab\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStu
 dy: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus
  Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants Wit
 h Resected PDAC\nEstimated primary completion: 1 January 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05968326
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05626114-11330@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:OpRegen: Phase 2 readout est. (NCT05626114)
DESCRIPTION:OpRegen\, phase 2\, Geographic Atrophy.\nStudy: A Study to Opti
 mize Subretinal Surgical Delivery and to Evaluate Safety and Activity of O
 pregen in Participants With Geographic Atrophy Secondary to Age-Related Ma
 cular Degeneration (GAlette)\; Adaptive Optics (AO) Retinal Imaging Substu
 dy in Association With Study GR44251\nEstimated primary completion: 1 Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/opregen#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05626114
URL:https://assetmemo.bio/drug/opregen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918846-159@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20310320
DTEND;VALUE=DATE:20310321
SUMMARY:enicepatide: Phase 3 readout est. (NCT07918846)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study Testi
 ng Enicepatide in Participants Living With Overweight or Obesity and Cardi
 ovascular Disease\nEstimated primary completion: 20 March 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07918846
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: A Study of Com
 bination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With and
  Without Bortezomib) in Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-2217@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Divarasib: Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Divarasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating the Safety\, Activity\, and Pharmacokinetics of Divarasib 
 as a Single Agent or in Combination With Other Anti-Cancer Therapies in Pa
 rticipants With Previously Untreated Advanced or Metastatic Non-Small Cell
  Lung Cancer With a KRAS G12C Mutation\nEstimated primary completion: 29 J
 anuary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/divarasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 789082
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541170-2217@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Divarasib: Phase 3 readout est. (NCT07541170)
DESCRIPTION:Divarasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy and Safety of Divarasib Compared With Investig
 ator's Choice of Immunotherapy or Observation in Participants With Resecte
 d Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 31 January 2032. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07541170
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790693-2545@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT06790693)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study Evaluating the Efficacy and Safety of Inavolisib Plu
 s CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Par
 ticipants With Endocrine-Sensitive PIK3CA-Mutated\, Hormone Receptor-Posit
 ive\, HER2-Negative Advanced Breast Cancer\nEstimated primary completion: 
 31 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inav
 olisib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06790693
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774718-2016@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320228
DTEND;VALUE=DATE:20320229
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT04774718)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2.\nStudy: A Study Evaluating th
 e Safety\, Pharmacokinetics\, and Efficacy of Alectinib in Pediatric Parti
 cipants With ALK Fusion-Positive Solid or CNS Tumors\nEstimated primary co
 mpletion: 28 February 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04774718
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2078@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity When Intravenous
  (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and 
 IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Le
 ukemia (AML)\nEstimated primary completion: June 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07581002
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541079-9126@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Giredestrant: Phase 3 readout est. (NCT07541079)
DESCRIPTION:Giredestrant\, phase 3.\nStudy: A Study Evaluating Adherence\, 
 Tolerability\, and Patient Reported Outcomes of Giredestrant in Participan
 ts With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aroma
 tase Inhibitor Therapy (novERA Breast Cancer)\nEstimated primary completio
 n: 30 June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gire
 destrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07541079
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717411-670@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320730
DTEND;VALUE=DATE:20320731
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07717411)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression
  to Symptomatic Alzheimer's Disease\nEstimated primary completion: 30 July
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trontinemab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077174
 11
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Tumor-agnostic Precision Immuno
 -oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
 \nEstimated primary completion: 25 September 2032. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223697-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:afimkibart: Phase 2 readout est. (NCT07223697)
DESCRIPTION:afimkibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long Term E
 xtension Study to Evaluate the Safety and Efficacy of Afimkibart (RO779012
 1) in Participants With Atopic Dermatitis\nEstimated primary completion: 1
  March 2033. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/afimkiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7223697
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-1962@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Rollover Study for Participan
 ts Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored
  Study\nEstimated primary completion: 1 March 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-10973@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:bexobrutideg: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:bexobrutideg\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Study of NX-5948 in Combination With Other Agents in Adults With B-cell 
 Malignancies\nEstimated primary completion: May 2033. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620392-20@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20330708
DTEND;VALUE=DATE:20330709
SUMMARY:afimkibart: Phase 2 readout est. (NCT07620392)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: An Extensi
 on Study to Assess Long-Term Safety and Efficacy of Afimkibart in Particip
 ants With Rheumatoid Arthritis\nEstimated primary completion: 8 July 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07620392
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987449-11331@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20331211
DTEND;VALUE=DATE:20331212
SUMMARY:Zemocimig: Phase 1/2 readout est. (NCT05987449)
DESCRIPTION:Zemocimig\, phase 1/2.\nStudy: A Study to Evaluate the Safety\,
  Tolerability\, Pharmacokinetics\, Pharmacodynamics\, and Efficacy of NXT0
 07 in Persons With Severe or Moderate Hemophilia A\nEstimated primary comp
 letion: 11 December 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zemocimig#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05987449
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
